| Japanese |
|---|
| Title | 骨核医学 |
|---|
| Subtitle | 総説 |
|---|
| Authors | 山本逸雄* |
|---|
| Authors(kana) | |
|---|
| Organization | *滋賀医科大学放射線科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 32 |
|---|
| Number | 5 |
|---|
| Page | 523-529 |
|---|
| Year/Month | 1995/5 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」骨核医学の中心は骨シンチグラフィであり, 99mTc-リン酸化合物による骨シンチグラフィは, 開発後すでに20年以上たち, その臨床的評価はかたまり, 日常の臨床に最もしばしば用いられる核医学検査となっている. その各疾患における意義は確立されているが, 近年の, イメージング機器の改良は, その価値をさらに高めている. また, 骨シンチグラフィと並んで, 近年著しい発展を見せている骨量計測は, 骨核医学の一方の柱となりつつある. DXA法は正確に, 骨量計測が可能であり, 骨粗鬆症の診療に重要な役割を果たしている. さらに, インビトロの分野では, 骨代謝マーカーの開発が盛んであり, より特異的, かつ, 高感度の骨形成あるいは骨吸収マーカーが続々と登場してきている. 骨代謝マーカーの応用は, 骨粗鬆症をはじめ, 骨疾患すべてに及ぶが, 転移性骨腫瘍の診断, 特に, 骨シンチグラフィの適応決定などに用いられる可能性がある. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Bone scintigraphy, Bone densitometry, Bone metabolic marker. |
|---|
| English |
|---|
| Title | Skeletal Nuclear Medicine |
|---|
| Subtitle | |
|---|
| Authors | Itsuo YAMAMOTO |
|---|
| Authors(kana) | |
|---|
| Organization | Shiga University of Medical Science |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 32 |
|---|
| Number | 5 |
|---|
| Page | 523-529 |
|---|
| Year/Month | 1995/5 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | Bone scintigraphy with 99mTc-phosphate compounds is the most popular examination in clinical nuclear medicine. This was developed more than 20 years ago and its roles in various skeletal disorders are well established. Furthermore, improvement of imaging apparatus and application of SPECT strengthened its value extensively. From scintigram alone, in many cases, differentiation between bone metastasis and other "benign" disorders is easily capable. Further improvement in resolution of scinticamera should strengthen its value more. Other recent developments in skeletal nuclear medicine are those in bone densitometry and in measurement of metabolic bone markers. Bone densitometry using DXA is applied on diagnosis and monitoring of therapeutic effects in various metabolic bone diseases, especially, in osteoporosis. Bone mass measurement combined with assessments of specific bone markers such as bone specific alkaline phosphatase and collagen cross-link metabolites might replace the bone biopsy in evaluating bone metabolism. Treatment of bone metastasis in patients with prostate cancer by administering radiolabeled bone seeking substances is another topics in this field and awaits for more extensive clinical evaluation. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Bone scintigraphy, Bone densitometry, Bone metabolic marker. |
|---|